Jones Financial Companies
TVTX icon

Jones Financial Companies’s Travere Therapeutics TVTX Stock Holding History

Jones Financial Companies’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.2K Buy
632
+457
+261% +$13.7K ﹤0.01% 3347
2025
Q4 		$6.69K Buy
175
+107
+157% +$3.48K ﹤0.01% 3392
2025
Q3 		$1.72K Buy
+68
New +$1.28K ﹤0.01% 3743
2025
Q2 		– Sell
-722
Closed -$14.2K – 4160
2025
Q1 		$14.2K Buy
+722
New +$14.7K ﹤0.01% 2558

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jones Financial Companies's TVTX Position: Q1 2026 in Review

Jones Financial Companies increased its Travere Therapeutics (TVTX) stake by 261% in Q1 2026, buying an estimated $13.7K and bringing the position to 632 shares worth $17.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3347.

Jones Financial Companies first reported a position in TVTX in Q1 2025 and has held it in 4 quarters since. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Jones Financial Companies held 632 shares of Travere Therapeutics worth $17.2K as of Q1 2026.
  • Jones Financial Companies bought 457 Travere Therapeutics shares in Q1 2026, an estimated $13.7K.
  • Travere Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #3347 holding.
  • Jones Financial Companies first reported a position in Travere Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.